(19)
(11) EP 1 420 787 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
01.09.2010 Bulletin 2010/35

(45) Mention of the grant of the patent:
23.12.2009 Bulletin 2009/52

(21) Application number: 02767419.1

(22) Date of filing: 22.08.2002
(51) International Patent Classification (IPC): 
A61K 31/445(2006.01)
A61K 47/34(2006.01)
A61K 31/435(2006.01)
 A61K 47/32(2006.01)
A61K 9/00(2006.01)
(86) International application number:
PCT/EP2002/009408
(87) International publication number:
WO 2003/017990 (06.03.2003 Gazette 2003/10)

(54)

OPHTHALMIC COMPOSITION COMPRISING AN ASCOMYCIN

ASCOMYCIN ENTHALTENDE OPHTHALMISCHE ZUBEREITUNGEN

COMPOSITIONS OPHTALMIQUES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
Designated Extension States:
RO SI

(30) Priority: 23.08.2001 US 314448 P

(43) Date of publication of application:
26.05.2004 Bulletin 2004/22

(73) Proprietors:
  • Novartis AG
    4056 Basel (CH)
    Designated Contracting States:
    BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR 
  • Novartis Pharma GmbH
    1230 Wien (AT)
    Designated Contracting States:
    AT 

(72) Inventors:
  • WONG, Michelle, Pik-han
    Duluth, GA 30096 (US)
  • MINICK, Kasey, Jon
    Morrisville, NC 27560 (US)
  • BABIOLE SAUNIER, Maggy
    F-68130 Jettingen (FR)
  • BIZEC, Jean-Claude
    F-68440 Habsheim (FR)
  • FETZ, Andrea
    CH-8620 Wetzikon (CH)
  • SCHOCH, Christian
    CH-4132 Muttenz (CH)

(74) Representative: de Weerd, Petrus G.W. et al
Novartis International AG Corporate Intellectual Property
4002 Basel
4002 Basel (CH)


(56) References cited: : 
EP-A- 0 551 626
WO-A-99/34830
 WO-A-96/13249
   
  • LIN H-R ET AL: "Carbopol/pluronic phase change solutions for ophthalmic drug delivery" JOURNAL OF CONTROLLED RELEASE, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 69, no. 3, 3 December 2000 (2000-12-03), pages 379-388, XP004221288 ISSN: 0168-3659
  • ZIGNANI M ET AL: "TOPICAL SEMI-SOLID DRUG DELIVERY: KINETICS AND TOLERANCE OF OPHTHALMIC HYDROGELS" ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, vol. 16, no. 1, 1995, pages 51-60, XP000653437 ISSN: 0169-409X
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).